AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06298279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tunneled Delivery
Description: Participants will be offered a pre-determined pathway to completing the 8-week course
Study NCT06298279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Delivery
Description: Participants will be able to complete course modules at their own pace and in the order that most interests them.
Study NCT06298279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Resources
Description: Participants will receive the resources as typically included in the Self-Guided PSP Wellbeing Course.
Study NCT06298279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Social Learning Resources
Description: Participants will receive additional intervention content.
Study NCT06298279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Self-Guided ICBT
Description: An ICBT course that is completed without the guidance of a therapist.
Study NCT05016076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg
Description: In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.
Study NCT05016076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Applied inspiratory pressure (10, 15, 20, or 25 cmH2O)
Description: A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea determined by end-tidal capnography occurs, a mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure (PEEP), at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator (Carestation 620, Datex-Ohmeda, Inc., Madison, WI, USA).
Study NCT05016076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopy
Description: In video intubating stylet group, a tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved. In video laryngoscopy group, a tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients. In direct laryngoscopy group, tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
Study NCT05016076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goal-directed hemodynamic therapy targeting cardiac index
Description: Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2. In brief, if cardiac index \< 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is \< 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
Study NCT05016076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Description: Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
Study NCT04344054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB
Description: 1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age
Study NCT04344054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age
Study NCT04344054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: 1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.
Study NCT04344054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV3-BB birth dose
Description: 1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.
Study NCT04344054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8 Booster dose
Description: 0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
Study NCT06467500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104)
Description: Subjects participated in a study where they received cadonilimab intravenously at 6mg/kg every two weeks, prepared in 100mL of normal saline (0.9% NaCl), with a final concentration range of 0.2-5.0mg/mL. The infusion solution must be used within 4 hours of preparation. Treatment continued until disease progression (PD), unacceptable toxicity, or 24 months, whichever came first. Patients who investigators deemed could still benefit from cadonilimab post-PD were allowed continued treatment. Chemotherapy regimens were selected by investigators based on prior medication use, including gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine as second- or third-line therapy
Study NCT05481580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontal probing
Description: The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment
Study NCT06232863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH009
Description: Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
Study NCT04335110 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)
Description: STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
Study NCT05516212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAFMONO supplementation
Description: CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND
Study NCT05516212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAFMIPS_1 supplementation
Description: CAFMIPS_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND
Study NCT05516212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAFMIPS_2 supplementation
Description: CAFMIPS_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY.
Study NCT05516212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
Study NCT05880563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-RoSMA-18-d6
Description: \[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
Study NCT05491174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-Informed skills group
Description: 10 session group ran weekly by junior staff (P-BIFs) following a standardised manual-based protocol which can be delivered either face-to-face or via video-call. The groups will be skills-based, covering each of the four modules of DBT: Mindfulness, Distress Tolerance, Emotion Regulation and Interpersonal Effectiveness.
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Vincristine
Description: dose 1.5 mg/m2 at days 1, 8, 15 and 22
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: 40 mg on days 1-2, 8-9,15-16 and 22-23
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Imatinib
Description: 600 mg per day from 1 to up to 5 years
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Cytarabine
Description: 1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Mercaptopurine
Description: 50 mg/m2 on days 1 to 28 of maintenance
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: 1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Ponatinib
Description: 15 mg per day from consolidation start up to 5 years
Study NCT06175702 — intervention group
Intervention type: PROCEDURE
Intervention: allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.
Study NCT06175702 — intervention group
Intervention type: PROCEDURE
Intervention: Total body irradiation
Description: Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: 60 mg/kg on days -6 and -5 before alloSCT
Study NCT06175702 — intervention group
Intervention type: DRUG
Intervention: Fludarabine
Description: 30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
Study NCT05974020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention will be applied to the control group, and information will be given on general foot care instructions and the use of appropriate shoes.
Study NCT05974020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrinsic Muscle Training
Description: In addition to general foot care instructions and briefings on the use of appropriate shoes, intrinsic muscle training including alternating toe movement, toes picking up sheets, opening and closing the toes, pinching the toe separators, toe transitions and short foot exercises will be implemented.~Additionaly, warm-up exercises, ankle exercises and functional exercises will be included in the program.
Study NCT04981665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg IV Q3W
Study NCT04981665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed after curative resection (4±1w)
Study NCT05974020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: In addition to general foot care instructions and information on the use of appropriate shoes, warm-up exercises, ankle exercises, functional exercises and intrinsic muscle training, the participants will be given a walking program for aerobic exercise.
Study NCT04878874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back
Study NCT04878874 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology Tape
Description: Kinesiology Tape is applied without creating any tension over low back
Study NCT05913388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: Administered orally twice daily at 400mg.
Study NCT05913388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a fixed dose of 200 mg every 3 weeks intravenously.
Study NCT05913388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Administered at a fixed dose of 200 mg every 3 weeks intravenously.
Study NCT05913388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally twice daily at 400mg.
Study NCT04873349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)
Description: two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
Study NCT04873349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)
Description: two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
Study NCT04805281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.
Description: wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
Study NCT04805281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Dislicate IPS e.max crown
Description: wear of lithium disilicate IPS e.max crown in posterior teeth
Study NCT05493033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomotic after LRC
Description: Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
Study NCT05493033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomotic after LRC
Description: The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
Study NCT05829902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal extract drink
Description: 30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily
Study NCT05829902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
Study NCT05267041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire between diagnostic annoucement and first line treatement
Study NCT05267041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
Study NCT05267041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire 6 months later after first line treatment
Study NCT05267041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire before second line treatment
Study NCT05267041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: One questionnaire 6 months later after second line treatment
Study NCT05054361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose/Mannitol Test
Description: After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
Study NCT06155669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
Study NCT05726526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIEWER virtual care platform
Description: VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
Study NCT05062239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative
Description: Discontinuance of prior statin therapy
Study NCT05062239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No-intervention.
Description: Continuance of prior statin therapy
Study NCT04922502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard SPACE
Description: 12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
Study NCT04922502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bibliotherapy, low therapist contact SPACE
Description: 4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD.
Study NCT04338152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)
Description: Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
Study NCT04338152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care (EC)
Description: Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
Study NCT04761458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Olfactory function testing
Description: Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
Study NCT04761458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Edmonton Frail Scale
Description: The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.